Economic Atlas
Companies/Pliant Therapeutics, Inc.
Company profile

Pliant Therapeutics, Inc.

NASDAQ: PLRX · Healthcare · Biotechnology
PublicHQ South San Francisco, CA · San MateoCIK 0001746473Reports USD
#1166 of 1,422 Healthcare companies by revenue
EA Score
48D
Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$149.3M
Employees
49
as of 2026-08-19
Market cap
$71.2M
as of 2026-08-19

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$0$02025
Net income-$149.3M-$149.3M2025
Operating income-$156.4M-$156.4M2025
Total assets$225.2M$225.2M2025
Liabilities$44.0M$44.0M2025
Equity$181.2M$181.2M2025

Revenue trend

FY2020 – FY2025 · USD
FY20
FY20
FY21
FY22
FY23
FY24
FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Pliant Therapeutics, Inc.’s revenue?

Pliant Therapeutics, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare
MAIA Biotechnology, Inc.34DvTv Therapeutics Inc.57CAnnovis Bio, Inc.32DXBiotech Inc.47DEloxx Pharmaceuticals, Inc.29DEdesa Biotech, Inc.47D
Neighbors
San Mateo →
Meta Platforms, Inc.$201.0B86AGilead Sciences, Inc.$29.4B87AEquinix, Inc.$9.2B74BRobinhood Markets, Inc.$4.5B67BElectronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$052D
Key facts
CEOBernard Coulie
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: PLRX
Employees49
IPO date2020-06-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.